Last $31.27 USD
Change Today -0.98 / -3.04%
Volume 65.2K
MC On Other Exchanges
New York
As of 8:04 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

moelis & co - class a (MC) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - $36.27
52 Week Low
04/21/14 - $25.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MOELIS & CO - CLASS A (MC)

moelis & co - class a (MC) Related Businessweek News

View More BusinessWeek News

moelis & co - class a (MC) Details

Moelis & Company provides strategic and financial advisory services in the United States and internationally. It advises clients in the areas of mergers and acquisitions, recapitalizations and restructurings, and other corporate finance matters. The company offers its services to public multinational corporations, governments, financial sponsors, middle market private companies, and individual entrepreneurs. Moelis & Company was founded in 2007 and is based in New York, New York.

550 Employees
Last Reported Date: 02/27/15
Founded in 2007

moelis & co - class a (MC) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $3.0M
Co-Founder, Managing Director and Director
Total Annual Compensation: $3.0M
Co-Founder, Managing Director, Head of Merger...
Total Annual Compensation: $3.0M
Compensation as of Fiscal Year 2013.

moelis & co - class a (MC) Key Developments

Ocwen Financial Corporation Considering Multiple Strategic Alternatives

Ocwen Financial Corp. (NYSE:OCN) is considering multiple strategic alternatives. “Ocwen Financial Corporation has appointed Moelis & Company and Barclays Capital Inc. to help it explore “strategic options,” Ocwen Financial Corporation said February 3, 2015 in a statement.

Moelis & Company Appoints Yvonne Greenstreet as Independent Member of Board of Directors

Moelis & Company announced the appointment of Dr. Yvonne Greenstreet as an independent member of the Board of Directors. Dr. Greenstreet has over 20 years of experience in the pharmaceutical industry and has held senior roles in research and development, strategy, commercial development and portfolio management. She was formerly Senior Vice President and Head of Medicines Development for Pfizer where she was a member of the Specialty Business global executive team. Dr. Greenstreet also spent 18 years at GlaxoSmithKline, most recently as Senior Vice President and Chief of Strategy for Research and Development and a member of the corporate portfolio management board. She held a variety of positions at GlaxoSmithKline prior to this, including Chief Medical Officer for Europe.

Moelis & Company Declares Quarterly Dividend, Payable on March 6, 2015

On February 3, 2015, the Board of Directors of Moelis & Company declared a quarterly dividend of $0.20 per share. The dividend will be paid on March 6, 2015 to common stockholders of record on February 20, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MC:US $31.27 USD -0.98

MC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Credit Suisse Group AG SFr.23.13 CHF +0.18
Evercore Partners Inc $51.05 USD -0.55
Greenhill & Co Inc $37.43 USD -0.57
Lazard Ltd $50.08 USD -0.87
Blackstone Group LP/The $38.61 USD +0.76
View Industry Companies

Industry Analysis


Industry Average

Valuation MC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 5.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOELIS & CO - CLASS A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at